Comparison of green tea and metformin effects on anthropometric indicators in women with polycystic ovarian syndrome: A clinical trial study
Abstract
Background: Polycystic ovary syndrome (PCOS), as a complex reproductive and endocrinological disorder, affects up to one in five women. Treatment for obesity in women with this syndrome is necessary due to the occurrence of various complications, especially infertility. Recently, green tea with many health benefits, as a natural herbal medicine, has been widely considered in treating various diseases. Objective: This clinical study was planned to compare the effect of green tea and metformin treatment on the anthropometric indices of women with PCOS. Materials and Methods: In this double-blind, randomized clinical trial, 45 women among 18–35 years of age with PCOS referring to the endometriosis center of Fatemieh Hospital of Hamadan, Iran, who had the eligibility criteria for entering the study, were randomized into three study groups: the green tea, the metformin group, and the control group. Weight, body mass index (BMI), waist circumference, hip circumference, and waist-to-hip ratio, before, 1 month later, and 3 months after intervention in each group were measured. Data were statistically analyzed using Statistical Package for the Social Sciences (SPSS) statistical software, version 23.0. Results: No statistically significant difference was observed between the three groups during the study period. A significant reduction of anthropometric indices, such as weight, BMI, waist, and hip circumference, was observed in the green tea group. Conclusion: The use of green tea for…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 45 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.